ChemicalBook >> CAS DataBase List >>Abemaciclib


Chemical Name:
N-[5-[(4-Ethyl-1-piperazinyl)methyl]-2-pyridinyl]-5-fluoro-4-[4-fluoro-2-methyl-1-(1-methylethyl)-1H-benzimidazol-6-yl]-2-pyrimidinamine;Abemaciclib (LY2835219);N-(5-((4-Ethylpiperazin-1-yl)methyl)pyridin-2-yl)-5-fluoro-4-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)pyrimidin-2-amine;CS-814;abecilee;Abemaciclib;Abemaciclib D7;Abemaciclib D10;ABEMACICLIB BASE;Abemaciclib, >=98%
Molecular Formula:
Molecular Weight:
MDL Number:
MOL File:
Last updated:2024-05-27 13:38:20

Abemaciclib Properties

Boiling point 689.3±65.0 °C(Predicted)
Density 1.32±0.1 g/cm3(Predicted)
storage temp. 4°C, protect from light
solubility insoluble in H2O; ≥4.83 mg/mL in DMSO with gentle warming and ultrasonic; ≥6.34 mg/mL in EtOH with gentle warming
form solid
pka 7.69±0.10(Predicted)
NCI Dictionary of Cancer Terms abemaciclib
NCI Drug Dictionary abemaciclib
ATC code L01EF03


Risk and Safety Statements

Symbol(GHS)  GHS hazard pictograms
Signal word  Danger
Hazard statements  H373-H360-H410
Precautionary statements  P273-P391-P501-P260-P314-P501
NFPA 704
2 0

Abemaciclib price More Price(25)

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
Cayman Chemical 21560 LY2835219 ≥98% 1231929-97-7 1mg $37 2024-03-01 Buy
Cayman Chemical 21560 LY2835219 ≥98% 1231929-97-7 5mg $142 2024-03-01 Buy
Cayman Chemical 21560 LY2835219 ≥98% 1231929-97-7 10mg $231 2024-03-01 Buy
Cayman Chemical 21560 LY2835219 ≥98% 1231929-97-7 25mg $530 2024-03-01 Buy
TRC A115153 Abemaciclib 1231929-97-7 50mg $95 2021-12-16 Buy
Product number Packaging Price Buy
21560 1mg $37 Buy
21560 5mg $142 Buy
21560 10mg $231 Buy
21560 25mg $530 Buy
A115153 50mg $95 Buy

Abemaciclib Chemical Properties,Uses,Production


Class: serine/threonine protein kinase
Treatment: Breast cancer
Oral bioavailability = 46%
Elimination half-life = 18 h
Protein binding = 95–98%


Abemaciclib is a potent and selective inhibitor of cyclin-dependent kinases, CDK4 and CDK6, as a method to inhibit the proliferation of cancer cells.


Abemaciclib is used to treat breast cancer that is estrogen receptor-positive (ER-positive) and HER2-negative. It can be taken by both men and women. Patients may be offered abemaciclib if they have:
Early primary breast cancer that the treatment team thinks has a higher risk of coming back (recurrence). Abemaciclib may be provided as an adjuvant treatment, meaning a treatment given after initial treatment, such as surgery;
Breast cancer that has spread to the tissues and lymph nodes around the chest, neck, and under the breastbone (locally advanced breast cancer);
Breast cancer has spread to other parts of the body, such as the bones, lungs, liver, or brain (secondary breast cancer).

Biological Activity

ly2835219 is an orally available cyclin-dependent kinase (cdk) inhibitor that targets the cdk4 (cyclin d1) and cdk6 (cyclin d3) cell cycle pathway, with potential antineoplastic activity. cdk4/6 dual inhibitor ly2835219 specifically inhibits cdk4 and 6, thereby inhibiting retinoblastoma (rb) protein phosphorylation in early g1. inhibition of rb phosphorylation prevents cdk-mediated g1-s phase transition, thereby arresting the cell cycle in the g1 phase, suppressing dna synthesis and inhibiting cancer cell growth. overexpression of the serine/threonine kinases cdk4/6, as seen in certain types of cancer, causes cell cycle deregulation.

Biochem/physiol Actions

LY2835219 (abemaciclib) was identified via compound and biochemical screening by scientists at Eli Lilly and Company Research Laboratories and selected for its biological activity and highly selective inhibition of the complexes CDK4/ cyclin D1 (IC50 =2 nmol/L) and CDK6/cyclin D1 (IC50 =10 nmol/L), with no activity against other CDK/cyclin complexes or cell-cycle-related kinases within the nanomolar ranges, except for inhibition of CDK9 at IC50 at least five times higher. The compound was shown to act as a competitive inhibitor of the ATP-binding domain of the CDK4 and CDK6 and to be 14 times more potent against CDK4 than against CDK6. In comparison to palbociclib and ribociclib, abemaciclib shows higher selectivity for the complex CDK4/cyclin D1, with IC50 values five times lower than those of the two other compounds[1].


A concise total synthesis of CDK 4/6 inhibitor abemaciclib is described below. The synthesis uses a Suzuki coupling and a Hartwig–Buchwald amination to join three of the four subunits. The final step is a reductive amination utilizing Leuckart–Wallach conditions. Key to the Leuckart–Wallach reaction was the addition of trimethyl orthoformate to remove water formed during the reaction, allowing the reaction to complete[4].

Enzyme inhibitor

This oral cell cycle inhibitor (FWfree-base = 506.61 g/mol; FWmesylate-salt = 602.70 g/mol; CAS 1231930-82-7 (mesylate salt) ), also known as LY2835219 and N-[5-[ (4-ethyl-1-piperazinyl) methyl]-2-pyridinyl]-5- fluoro-4-[4-fluoro-2-methyl-1- (1-methylethyl) -1H-benzimidazol-6-yl]-2- pyrimidinamine, targets the cyclin-dependent kinase CDK4, or cyclin D1 (IC50 = 2 nM) and CDK6, or cyclin D3 (IC50 = 6 nM), inhibiting retinoblastoma (Rb) protein phosphorylation in early G1, thereby arresting the cell cycle in the G1, suppressing DNA synthesis, and inhibiting cancer cell growth. LY2835219 inhibits activation of AKT and ERK, but not mTOR.


[1] Silvia Paola Corona, Daniele Generali. “Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2- advanced breast cancer.” Drug Design, Development and Therapy (2018): 321–330.
[2] “OS Trending Positive for Abemaciclib.” Cancer discovery 13 1 (2023): OF3.
[3] Erin R Scheidemann. “Resistance to abemaciclib is associated with increased metastatic potential and lysosomal protein deregulation in breast cancer cells.” Molecular Carcinogenesis (2024): 209–223.
[4] Michael O. Frederick, Douglas P. Kjell. “A synthesis of abemaciclib utilizing a Leuckart–Wallach reaction.” Tetrahedron Letters 56 7 (2015): Pages 949-951.

Synthesis of Abemaciclib from 5-((4-Ethylpiperazin-1-yl)methyl)pyridin-2-amine and 6-Bromo-4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazole
Global( 274)Suppliers
Supplier Tel Email Country ProdList Advantage
Beijing Hope Pharmaceutical Co., Ltd.
+86-010-67886402 +8613611125266 China 71 58
Arizest(Shanghai)Pharmatech Co., Ltd
+86-021-60753300 China 220 58
Hebei Yanxi Chemical Co., Ltd.
+8617531190177 China 6011 58
shandong perfect biotechnology
+86-53169958659; +8618596095638 China 294 58
Henan Bao Enluo International TradeCo.,LTD
+86-17331933971 +86-17331933971 China 2503 58
Henan Tianfu Chemical Co.,Ltd.
+86-0371-55170693 +86-19937530512 China 21689 55
Hangzhou FandaChem Co.,Ltd.
008657128800458; +8615858145714 China 9341 55
+undefined-21-51877795 China 32686 60
career henan chemical co
+86-0371-86658258 China 29914 58
0086-13720134139 CHINA 967 58

Related articles

View Lastest Price from Abemaciclib manufacturers

Image Update time Product Price Min. Order Purity Supply Ability Manufacturer
Abemaciclib pictures 2024-05-10 Abemaciclib
US $0.00-0.00 / g 50g 99%HPLC 5Kg Arizest(Shanghai)Pharmatech Co., Ltd
Abemaciclib pictures 2024-03-12 Abemaciclib
US $0.00 / g 1g 98% HPLC 1kg shandong perfect biotechnology
Abemaciclib pictures 2023-10-11 Abemaciclib
US $0.00 / kg 1kg 0.99 20tons Hebei Yanxi Chemical Co., Ltd.
  • Abemaciclib pictures
  • Abemaciclib
  • US $0.00-0.00 / g
  • 99%HPLC
  • Arizest(Shanghai)Pharmatech Co., Ltd
  • Abemaciclib pictures
  • Abemaciclib
  • US $0.00 / g
  • 98% HPLC
  • shandong perfect biotechnology
  • Abemaciclib pictures
  • Abemaciclib
  • US $0.00 / kg
  • 0.99
  • Hebei Yanxi Chemical Co., Ltd.

Abemaciclib Spectrum

Abemaciclib, >=98% Abemaciclib abemaciclib(CDK 4/6 inhibitor) Bemaciclib(LY2835219, abemaciclib) CDK4/6 dual inhibitor LY 2835219 (free base) LY2835219 (free base) LY-2835219 (free base) Bemaciclib(LY2835219free base N-[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]-5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyrimidin-2-amine LY2835219(Abemaciclib) 2-Pyrimidinamine,N-[5-[(4-ethyl-1-piperazinyl)methyl]-2-pyridinyl]-5-fluoro-4-[4-fluoro-2-methyl-1-(1-methylethyl)-1H-benzimidazol-6-yl]- ethyl-1-(propan-2-yl)-1H-benzimidazol-6-yl]pyrimidin-2-amine LY2835219free base,Abemaciclib Abemaciclib free base ABEMACICLIB BASE Abemaciclib Mesylate (Verzenio) CS-814 LY2835219;LY-2835219;LY 2835219;ABEMACICLIB;CDK4/6 DUAL INHIBITOR;LY-2835219 FREE BASE N-{5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl}-5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-1,3-benzodiazol-5-yl)pyrimidin-2-amine Abemaciclib D10 Abemaciclib D7 Abemaciclib (LY2835219) N-[5-[(4-Ethyl-1-piperazinyl)methyl]-2-pyridinyl]-5-fluoro-4-[4-fluoro-2-methyl-1-(1-methylethyl)-1H-benzimidazol-6-yl]-2-pyrimidinamine N-(5-((4-Ethylpiperazin-1-yl)methyl)pyridin-2-yl)-5-fluoro-4-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)pyrimidin-2-amine inhibit,LY-2835219,LY 2835219,Abemaciclib,Inhibitor,Cyclin dependent kinase,CDK 5-(4-ethylpiperazin-1-ylmethyl)pyridin-2-yl)-(5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3H-benzimidazol-5-yl)pyrimidin-2-yl)amine Abemaciclib Powder abecilee 1231929-97-7 C27H32F2N8 Inhibitors Pharmaceutical API 1231929-97-7